Weight Loss Drugs May Reduce Dementia, Stroke Risks

Weekly injections of GLP-1 receptor agonist for improved glucose regulation in type 2 diabetes

Photo: Iuliia Burmistrova / Moment / Getty Images

Recent research published in JAMA Network suggests that popular weight loss drugs, semaglutide and tirzepatide, may lower the risk of dementia and stroke in patients with Type Two diabetes and obesity. The study analyzed health developments over seven years in 60,000 adults, revealing that these medications were associated with a reduced risk of developing certain diseases compared to other medications. The effects were most noticeable among women, patients older than 60, and those with a body mass index (BMI) between 30 and 40. However, researchers emphasized the need for more clinical trials to confirm these initial findings.

The study highlights the potential benefits of these drugs beyond weight loss, offering hope for improved health outcomes in high-risk groups. As the research progresses, it may lead to new treatment strategies for managing both obesity and related health conditions.


Sponsored Content

Sponsored Content